Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cascadia Commences First Drill Test of 1,065 g/t Gold Outcrop at Catch Property (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CG Oncology Inc CGON

Healthcare Biotechnology
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CGON)

CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

GlobeNewswire 6 days ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire 8 days ago

SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

GlobeNewswire May 1, 2025

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

GlobeNewswire April 26, 2025

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

GlobeNewswire April 24, 2025

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

GlobeNewswire March 31, 2025

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

GlobeNewswire March 28, 2025

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

GlobeNewswire March 24, 2025

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

GlobeNewswire March 12, 2025
View More News ››

Opinion & Analysis (NDAQ:CGON)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CGON)

Be the first to post on this bullboard.

Patriot Responder Technologies

Patriot Responder Technologies

Patriot Responder, in collaboration with Virginia Commonwealth University (VCU), is addressing a critical gap in public ...
View More »